カテゴリ： QYResearch, 世界, 医療/バイオ

うつ病治療薬の世界市場2025年：SSRI、SNRI、その他

■ 英語タイトル：Global Depression Drugs Market Research Report 2025

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA7456）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA7456
■ 発行日：2025年3月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：86
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥417,600見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥626,400見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥835,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[うつ病治療薬の世界市場2025年：SSRI、SNRI、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料はうつ病治療薬のグローバル市場について調査・分析し、世界のうつ病治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（SSRI、SNRI、その他）、用途別セグメント分析（病院、クリニック、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Intellipharmaceutics、Pfizer、Eli Lilly、Astrazeneca、Lundbeck、Allergan、GSK、Otsuka Pharmaceutical、Takeda、NHU Group、Shionogi、APOTEX、Kanghong Pharma、HUAHAIなどが含まれています。うつ病治療薬のグローバル市場は、2024年にXXX米ドル、2031年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。貿易戦争とロシア・ウクライナ戦争の影響は、うつ病治療薬市場規模を算出する際に考慮しました。

・うつ病治療薬市場の概要
- うつ病治療薬の種類別セグメント
- 世界のうつ病治療薬市場規模：タイプ別分析（SSRI、SNRI、その他）
- うつ病治療薬の用途別セグメント
- 世界のうつ病治療薬市場規模：用途別分析（病院、クリニック、その他）
- 世界のうつ病治療薬市場規模予測（2020年-2031年）

・うつ病治療薬市場の成長トレンド
- うつ病治療薬の地域別市場規模（2020年-2031年）
- うつ病治療薬市場ダイナミクス
- うつ病治療薬の業界動向
- うつ病治療薬市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：SSRI、SNRI、その他
- 世界のうつ病治療薬のタイプ別市場規模（2020年-2025年）
- 世界のうつ病治療薬のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、クリニック、その他
- 世界のうつ病治療薬の用途別市場規模（2020年-2025年）
- 世界のうつ病治療薬の用途別市場規模（2024年-2029年）

・うつ病治療薬の地域別市場規模
- 北米のうつ病治療薬市場規模（2020年-2031年）
- 米国のうつ病治療薬市場規模（2020年-2031年）
- ヨーロッパのうつ病治療薬市場規模（2020年-2031年）
- アジア太平洋のうつ病治療薬市場規模（2020年-2031年）
- 中国のうつ病治療薬市場規模（2020年-2031年）
- 日本のうつ病治療薬市場規模（2020年-2031年）
- 韓国のうつ病治療薬市場規模（2020年-2031年）
- インドのうつ病治療薬市場規模（2020年-2031年）
- オーストラリアのうつ病治療薬市場規模（2020年-2031年）
- 中南米のうつ病治療薬市場規模（2020年-2031年）
- 中東・アフリカのうつ病治療薬市場規模（2020年-2031年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Intellipharmaceutics、Pfizer、Eli Lilly、Astrazeneca、Lundbeck、Allergan、GSK、Otsuka Pharmaceutical、Takeda、NHU Group、Shionogi、APOTEX、Kanghong Pharma、HUAHAI

・アナリストの観点/結論

・調査手法と情報源

Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.
Highlights
The global Depression Drugs market was valued at US$ 17670 million in 2024 and is anticipated to reach US$ 20980 million by 2031, witnessing a CAGR of 2.9% during the forecast period 2025-2031. The influence of trade war and the Russia-Ukraine War were considered while estimating market sizes.
Global Depression Drugs key players include Intellipharmaceutics, Pfizer, Eli Lilly, Astrazeneca, Lundbeck, etc. Global top five manufacturers hold a share over 35%.
North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share about 50%.
In terms of product, SSRIs is the largest segment, with a share over 45%. And in terms of application, the largest application is Hospitals, followed by Clinics, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Depression Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Depression Drugs.
The Depression Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Depression Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Depression Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Intellipharmaceutics
Pfizer
Eli Lilly
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
Kanghong Pharma
HUAHAI
Segment by Type
SSRIs
SNRIs
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Depression Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Depression Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 SSRIs
1.2.3 SNRIs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Depression Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Depression Drugs Market Perspective (2020-2031)
2.2 Depression Drugs Growth Trends by Region
2.2.1 Global Depression Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Depression Drugs Historic Market Size by Region (2020-2025)
2.2.3 Depression Drugs Forecasted Market Size by Region (2026-2031)
2.3 Depression Drugs Market Dynamics
2.3.1 Depression Drugs Industry Trends
2.3.2 Depression Drugs Market Drivers
2.3.3 Depression Drugs Market Challenges
2.3.4 Depression Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Depression Drugs Players by Revenue
3.1.1 Global Top Depression Drugs Players by Revenue (2020-2025)
3.1.2 Global Depression Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Depression Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Depression Drugs Revenue
3.4 Global Depression Drugs Market Concentration Ratio
3.4.1 Global Depression Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Depression Drugs Revenue in 2022
3.5 Depression Drugs Key Players Head office and Area Served
3.6 Key Players Depression Drugs Product Solution and Service
3.7 Date of Enter into Depression Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Depression Drugs Breakdown Data by Type
4.1 Global Depression Drugs Historic Market Size by Type (2020-2025)
4.2 Global Depression Drugs Forecasted Market Size by Type (2026-2031)
5 Depression Drugs Breakdown Data by Application
5.1 Global Depression Drugs Historic Market Size by Application (2020-2025)
5.2 Global Depression Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Depression Drugs Market Size (2020-2031)
6.2 North America Depression Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Depression Drugs Market Size by Country (2020-2025)
6.4 North America Depression Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Depression Drugs Market Size (2020-2031)
7.2 Europe Depression Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Depression Drugs Market Size by Country (2020-2025)
7.4 Europe Depression Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Depression Drugs Market Size (2020-2031)
8.2 Asia-Pacific Depression Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Depression Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Depression Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Depression Drugs Market Size (2020-2031)
9.2 Latin America Depression Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Depression Drugs Market Size by Country (2020-2025)
9.4 Latin America Depression Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Depression Drugs Market Size (2020-2031)
10.2 Middle East & Africa Depression Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Depression Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Depression Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Intellipharmaceutics
11.1.1 Intellipharmaceutics Company Detail
11.1.2 Intellipharmaceutics Business Overview
11.1.3 Intellipharmaceutics Depression Drugs Introduction
11.1.4 Intellipharmaceutics Revenue in Depression Drugs Business (2020-2025)
11.1.5 Intellipharmaceutics Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Depression Drugs Introduction
11.2.4 Pfizer Revenue in Depression Drugs Business (2020-2025)
11.2.5 Pfizer Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Depression Drugs Introduction
11.3.4 Eli Lilly Revenue in Depression Drugs Business (2020-2025)
11.3.5 Eli Lilly Recent Development
11.4 Astrazeneca
11.4.1 Astrazeneca Company Detail
11.4.2 Astrazeneca Business Overview
11.4.3 Astrazeneca Depression Drugs Introduction
11.4.4 Astrazeneca Revenue in Depression Drugs Business (2020-2025)
11.4.5 Astrazeneca Recent Development
11.5 Lundbeck
11.5.1 Lundbeck Company Detail
11.5.2 Lundbeck Business Overview
11.5.3 Lundbeck Depression Drugs Introduction
11.5.4 Lundbeck Revenue in Depression Drugs Business (2020-2025)
11.5.5 Lundbeck Recent Development
11.6 Allergan
11.6.1 Allergan Company Detail
11.6.2 Allergan Business Overview
11.6.3 Allergan Depression Drugs Introduction
11.6.4 Allergan Revenue in Depression Drugs Business (2020-2025)
11.6.5 Allergan Recent Development
11.7 GSK
11.7.1 GSK Company Detail
11.7.2 GSK Business Overview
11.7.3 GSK Depression Drugs Introduction
11.7.4 GSK Revenue in Depression Drugs Business (2020-2025)
11.7.5 GSK Recent Development
11.8 Otsuka Pharmaceutical
11.8.1 Otsuka Pharmaceutical Company Detail
11.8.2 Otsuka Pharmaceutical Business Overview
11.8.3 Otsuka Pharmaceutical Depression Drugs Introduction
11.8.4 Otsuka Pharmaceutical Revenue in Depression Drugs Business (2020-2025)
11.8.5 Otsuka Pharmaceutical Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Depression Drugs Introduction
11.9.4 Takeda Revenue in Depression Drugs Business (2020-2025)
11.9.5 Takeda Recent Development
11.10 NHU Group
11.10.1 NHU Group Company Detail
11.10.2 NHU Group Business Overview
11.10.3 NHU Group Depression Drugs Introduction
11.10.4 NHU Group Revenue in Depression Drugs Business (2020-2025)
11.10.5 NHU Group Recent Development
11.11 Shionogi
11.11.1 Shionogi Company Detail
11.11.2 Shionogi Business Overview
11.11.3 Shionogi Depression Drugs Introduction
11.11.4 Shionogi Revenue in Depression Drugs Business (2020-2025)
11.11.5 Shionogi Recent Development
11.12 APOTEX
11.12.1 APOTEX Company Detail
11.12.2 APOTEX Business Overview
11.12.3 APOTEX Depression Drugs Introduction
11.12.4 APOTEX Revenue in Depression Drugs Business (2020-2025)
11.12.5 APOTEX Recent Development
11.13 Kanghong Pharma
11.13.1 Kanghong Pharma Company Detail
11.13.2 Kanghong Pharma Business Overview
11.13.3 Kanghong Pharma Depression Drugs Introduction
11.13.4 Kanghong Pharma Revenue in Depression Drugs Business (2020-2025)
11.13.5 Kanghong Pharma Recent Development
11.14 HUAHAI
11.14.1 HUAHAI Company Detail
11.14.2 HUAHAI Business Overview
11.14.3 HUAHAI Depression Drugs Introduction
11.14.4 HUAHAI Revenue in Depression Drugs Business (2020-2025)
11.14.5 HUAHAI Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Depression Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of SSRIs
Table 3. Key Players of SNRIs
Table 4. Key Players of Others
Table 5. Global Depression Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Depression Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Depression Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Depression Drugs Market Share by Region (2020-2025)
Table 9. Global Depression Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Depression Drugs Market Share by Region (2026-2031)
Table 11. Depression Drugs Market Trends
Table 12. Depression Drugs Market Drivers
Table 13. Depression Drugs Market Challenges
Table 14. Depression Drugs Market Restraints
Table 15. Global Depression Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Depression Drugs Market Share by Players (2020-2025)
Table 17. Global Top Depression Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Depression Drugs as of 2022)
Table 18. Ranking of Global Top Depression Drugs Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Depression Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Depression Drugs Product Solution and Service
Table 22. Date of Enter into Depression Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Depression Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Depression Drugs Revenue Market Share by Type (2020-2025)
Table 26. Global Depression Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Depression Drugs Revenue Market Share by Type (2026-2031)
Table 28. Global Depression Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Depression Drugs Revenue Market Share by Application (2020-2025)
Table 30. Global Depression Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Depression Drugs Revenue Market Share by Application (2026-2031)
Table 32. North America Depression Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Depression Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Depression Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Depression Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Depression Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Depression Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Depression Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Depression Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Depression Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Depression Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Depression Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Depression Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Depression Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Depression Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Depression Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 47. Intellipharmaceutics Company Detail
Table 48. Intellipharmaceutics Business Overview
Table 49. Intellipharmaceutics Depression Drugs Product
Table 50. Intellipharmaceutics Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 51. Intellipharmaceutics Recent Development
Table 52. Pfizer Company Detail
Table 53. Pfizer Business Overview
Table 54. Pfizer Depression Drugs Product
Table 55. Pfizer Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 56. Pfizer Recent Development
Table 57. Eli Lilly Company Detail
Table 58. Eli Lilly Business Overview
Table 59. Eli Lilly Depression Drugs Product
Table 60. Eli Lilly Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 61. Eli Lilly Recent Development
Table 62. Astrazeneca Company Detail
Table 63. Astrazeneca Business Overview
Table 64. Astrazeneca Depression Drugs Product
Table 65. Astrazeneca Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 66. Astrazeneca Recent Development
Table 67. Lundbeck Company Detail
Table 68. Lundbeck Business Overview
Table 69. Lundbeck Depression Drugs Product
Table 70. Lundbeck Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 71. Lundbeck Recent Development
Table 72. Allergan Company Detail
Table 73. Allergan Business Overview
Table 74. Allergan Depression Drugs Product
Table 75. Allergan Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 76. Allergan Recent Development
Table 77. GSK Company Detail
Table 78. GSK Business Overview
Table 79. GSK Depression Drugs Product
Table 80. GSK Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 81. GSK Recent Development
Table 82. Otsuka Pharmaceutical Company Detail
Table 83. Otsuka Pharmaceutical Business Overview
Table 84. Otsuka Pharmaceutical Depression Drugs Product
Table 85. Otsuka Pharmaceutical Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 86. Otsuka Pharmaceutical Recent Development
Table 87. Takeda Company Detail
Table 88. Takeda Business Overview
Table 89. Takeda Depression Drugs Product
Table 90. Takeda Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 91. Takeda Recent Development
Table 92. NHU Group Company Detail
Table 93. NHU Group Business Overview
Table 94. NHU Group Depression Drugs Product
Table 95. NHU Group Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 96. NHU Group Recent Development
Table 97. Shionogi Company Detail
Table 98. Shionogi Business Overview
Table 99. Shionogi Depression Drugs Product
Table 100. Shionogi Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 101. Shionogi Recent Development
Table 102. APOTEX Company Detail
Table 103. APOTEX Business Overview
Table 104. APOTEX Depression Drugs Product
Table 105. APOTEX Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 106. APOTEX Recent Development
Table 107. Kanghong Pharma Company Detail
Table 108. Kanghong Pharma Business Overview
Table 109. Kanghong Pharma Depression Drugs Product
Table 110. Kanghong Pharma Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 111. Kanghong Pharma Recent Development
Table 112. HUAHAI Company Detail
Table 113. HUAHAI Business Overview
Table 114. HUAHAI Depression Drugs Product
Table 115. HUAHAI Revenue in Depression Drugs Business (2020-2025) & (US$ Million)
Table 116. HUAHAI Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Depression Drugs Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 2. Global Depression Drugs Market Share by Type: 2022 VS 2029
Figure 3. SSRIs Features
Figure 4. SNRIs Features
Figure 5. Others Features
Figure 6. Global Depression Drugs Market Size Comparison by Application (2025-2031) & (US$ Million)
Figure 7. Global Depression Drugs Market Share by Application: 2022 VS 2029
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Depression Drugs Report Years Considered
Figure 12. Global Depression Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Depression Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Depression Drugs Market Share by Region: 2022 VS 2029
Figure 15. Global Depression Drugs Market Share by Players in 2024
Figure 16. Global Top Depression Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Depression Drugs as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Depression Drugs Revenue in 2024
Figure 18. North America Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Depression Drugs Market Share by Country (2020-2031)
Figure 20. United States Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Depression Drugs Market Share by Country (2020-2031)
Figure 24. Germany Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Depression Drugs Market Share by Region (2020-2031)
Figure 32. China Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Depression Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Depression Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Depression Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Intellipharmaceutics Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 47. Pfizer Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 48. Eli Lilly Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 49. Astrazeneca Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 50. Lundbeck Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 51. Allergan Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 52. GSK Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 53. Otsuka Pharmaceutical Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 54. Takeda Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 55. NHU Group Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 56. Shionogi Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 57. APOTEX Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 58. Kanghong Pharma Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 59. HUAHAI Revenue Growth Rate in Depression Drugs Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

※参考情報

うつ病治療薬について、以下にその概念や特徴、種類、用途、関連技術などを詳しく解説します。

うつ病治療薬は、うつ病の症状を軽減したり、改善したりするために使用される薬剤です。うつ病は、気分が持続的に落ち込んだり、興味や喜びを感じられなくなったりする心理的な疾患であり、生活や日常活動に大きな影響を与えます。うつ病治療薬は、脳内の神経伝達物質のバランスを調整することで、これらの症状を改善することを目的としています。

うつ病治療薬には主にいくつかの種類があり、各薬剤はそれぞれ異なるメカニズムで作用します。最も一般的な種類は、選択的セロトニン再取り込み阻害薬（SSRI）です。SSRIは、脳内のセロトニンの量を増やすことによって効果を発揮します。セロトニンは気分に関連する神経伝達物質であり、正常な精神的健康には重要な役割を果たします。代表的なSSRIには、フルオキセチンやセルトラリンが含まれます。

次に、セロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）があります。このタイプの薬剤は、セロトニンだけでなくノルエピネフリンという別の神経伝達物質も増やすことで、うつ病の症状を軽減します。代表的なSNRIには、デュロキセチンやベンラファキシンが含まれます。これらの薬剤は、特に重度のうつ病や治療抵抗性のうつ病の患者に有効とされています。

また、三環系抗うつ薬（TCA）も存在します。このタイプの薬剤は、神経伝達物質の再取り込みを阻害する働きを持ちますが、副作用が比較的多いため、現在ではSSRIやSNRIに比べて使用されることが少なくなっています。代表的なTCAには、アミトリプチリンやイミプラミンがあります。

さらに、モノアミン酸化酵素阻害薬（MAOI）もあります。これは、脳内のモノアミン酸化酵素という酵素を阻害することによって、気分を改善する効果がありますが、特定の食品との相互作用があり、注意が必要です。

うつ病治療薬は、うつ病の治療だけでなく、他の精神疾患の治療にも使用されることがあります。例えば、強迫性障害やパニック障害、社会不安障害などの治療にも効果があります。このような場合でも、適切な診断と治療法が重要です。

うつ病治療薬の効果は、個々の患者により異なるため、医師がカスタマイズした治療を行うことが求められます。患者によっては、一つの薬剤が効果的である一方で、他の患者には効果が薄い場合もあります。そのため、臨床現場では患者の症状や特徴を考慮しながら、最適な薬剤を選択する必要があります。また、効果が見られるまでには数週間かかることが多く、その間は医師と患者が密にコミュニケーションをとることが求められます。

うつ病治療薬の使用にあたっては、副作用にも留意しなければなりません。一般的な副作用には、吐き気や頭痛、不眠、体重増加、性感情の低下などがあります。特にSSRIやSNRIでは、初期の数週間に副作用が出やすいですが、多くの場合は時間の経過とともに軽減します。しかし、つらい副作用が続く場合には、医師に相談することが重要です。最近では、副作用を軽減するための新たな薬剤や治療法の研究が進んでいます。

うつ病治療薬の進化には、その他の関連技術も深く関わっています。たとえば、遺伝子検査や生体マーカーの研究は、個々の患者に最適な薬剤を選択するための手助けになる可能性があります。遺伝子の違いによって、ある薬剤に対する反応が異なるため、パーソナライズされた治療が期待されています。また、脳刺激療法（TMSやECTなど）も、従来の薬物療法では効果が得られなかった患者にとって新たな選択肢を提供しています。

さらに、うつ病治療には心理療法も重要です。薬物療法と並行して行うことが多く、認知行動療法（CBT）や対人関係療法などが有名です。これらの治療法は、患者が自身の思考パターンや行動を見直し、改善するための助けとなります。

うつ病治療薬は、精神的な健康において重要な役割を果たしており、多くの患者にとって生活の質を向上させる手助けとなります。しかし、治療は一人ひとり異なり、適切な医療を提供することが求められます。最新の研究や治療法の進展を追っていくことで、今後のうつ病治療がさらに向上し、多くの人々がより良い生活を送れることを期待しています。以上が、うつ病治療薬に関する概念や特徴、種類、用途、関連技術などの解説になります。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • うつ病治療薬の世界市場（2022年～2032年）：非定型抗精神病薬、セロトニン-ノルエピネフリン再取り込み阻害薬（SNRI）、選択的セロトニン再取り込み阻害薬（SSRI）、中枢神経系（CNS）興奮薬、三環系抗うつ薬、モノアミンオキシダーゼ阻害薬、その他
  • セロトニンノルエピネフリン再取り込み阻害薬(SNRI)の世界市場2024
  • 自閉症スペクトラム症（ASD）治療のグローバル市場（2022年-2029年）：抗精神病薬、SSRI/抗うつ薬、興奮剤、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA7456 )"うつ病治療薬の世界市場2025年：SSRI、SNRI、その他" (英文：Global Depression Drugs Market Research Report 2025)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。